On February 4, 2026, Biodexa Pharmaceuticals Plc announced a license and collaboration agreement with Otsuka Pharmaceutical for developing the drug MTX240, aimed at treating gastrointestinal tumors, with upfront payments and royalties involved. This license covers worldwide rights excluding Japan, where Otsuka retains rights.